Team and Board of Trustees
Team and Board of Trustees
Board of Trustees
The FERO Cancer Board of Trustees.
The FERO Cancer Board of Trustees is composed of fifteen distinguished individuals, all convinced of the importance of translational oncology research and the role FERO Cancer plays in advancing this research in Spain.
Silvia Garriga Sels
Sol Daurella Comadrán
Àngels Miquel Vilanova
Lali Baselga Torres
Xavier Botet Campderrós
José Creuheras Margenat
Eusebio Díaz-Morera Puig-Sureda
Maria Macaya López-Mancisidor
Marian Puig Guasch
Mireia Tomàs Carulla
Juan Pablo Tornos Mas
Carmen Valle Mingorance
Management Team
The team that makes FERO Cancer's mission possible every day.
FERO Cancer operates with an intentionally small management structure. The goal is for the majority of funds raised to reach research, not administrative overhead. Management costs are minimal and audited annually.
Marta Cardona
Chief Executive Officer
Esther Aguilar
Scientific Management Director
Veronica Sagnier
Director of Private Philanthropy
Fernanda Rodríguez
Scientific Project Coordinator
Rebeca Arias
Accounting and Administrative Coordinator
Scientific Committee
The Scientific Advisory Committee. The guarantee of excellence in project selection.
The independence of the Scientific Committee is one of FERO Cancer’s fundamental pillars. Its members have no ties to the pharmaceutical industry and evaluate projects using the same criteria they apply in their own research and in the most impactful scientific publications.
Dr Josep Tabernero
Medical Oncologist, Head of the Medical Oncology Department at Vall d’Hebron Hospital and Director of the Vall d’Hebron Institute of Oncology (VHIO), Barcelona.
Dr. Aleix Prat
Oncólogo médico del Hospital Clínic de Barcelona,
Dr. Marisol Soengas
Microbiologist and Head of the Melanoma Group at the Spanish National Cancer Research Centre (CNIO), Madrid.
Dr. Luis Paz-Ares
Medical Oncologist, Head of the Medical Oncology Department at Hospital 12 de Octubre in Madrid and President of the Spanish Association for Cancer Research (ASEICA), Madrid.
Dr. Laura Soucek
Molecular Biologist and Geneticist, Head of the Anti-tumour Therapy Modelling Group at the Vall d’Hebron Institute of Oncology (VHIO), Barcelona.
Dr. Andrés Cervantes
Medical Oncologist, Full Professor of Medicine at the University of Valencia, Head of Medical Oncology Department at the University Clinical Hospital of Valencia, and Scientific Director of INCLIVA, Valencia.
Dr. Ruth Vera
Medical Oncologist, Head of the Medical Oncology Department at the Navarra Hospital Complex, specialist in digestive tumours, Pamplona.
Dr. Arkaitz Carracedo
Biologist and Principal Investigator of the Cell Signaling and Cancer Metabolism Group at the Cooperative Research Centre in Biosciences (CICbioGUNE), Bilbao.
Dr Óscar Fernández Capetillo
Biochemist, Head of the Genomic Instability Group and Deputy Director of the Spanish National Cancer Research Centre (CNIO), Madrid.
Dr. Eduard Batlle
Molecular Biologist, Head of the Colorectal Cancer Group and Coordinator of the Oncology Programme at the Institute for Research in Biomedicine (IRB), Barcelona.
Dr. Angela Nieto
Biochemist and Molecular Biologist, Director of the Cellular Movements in Physiology and Pathology Group at the Institute of Neurosciences (CSIC-UMH), Alicante.
Dr. Núria López-Bigas
Biologist Expert in Cancer Computational Genomics and Head of the Biomedical Genomics Group at the Institute for Research in Biomedicine (IRB), Barcelona.
Dr. Esther Aguilar
Biochemist and Director of Scientific Management at the FERO Foundation, Barcelona
Dr. Josep Tabernero
Director of VHIO — Vall d’Hebron Institute of Oncology
Specialty: Molecular Oncology
Dr. Aleix Prat
Clínic Barcelona Comprehensive Cancer Center
Specialty: Breast Cancer and Precision Medicine
Dr. Andrés Cervantes
INCLIVA — Hospital Clínico de Valencia
Specialty: Digestive Oncology
Dr. Luís Paz-Ares
Hospital 12 de Octubre · Madrid
Specialty: Lung Cancer
Dr. Antoni Ribas
International Expert
Specialty: Oncological Immunotherapy
External Scientific Committee
The External Scientific Advisory Committee.
Composed of internationally renowned experts who provide an independent and strategic vision of FERO Cancer’s scientific activities. They advise the Foundation on scientific planning, identify emerging opportunities and trends, and help ensure that FERO’s funding programs and initiatives align with best international practices and the most relevant advances in cancer research.
Dr Susan Galbraith
Executive Vice President of Oncology at AstraZeneca
Dr. Antoni Ribas
Director of the Tumor Immunology Program at the UCLA Jonsson Comprehensive Cancer Center. Professor of Medicine at the University of California, Los Angeles (UCLA).
Dr. Eva Hernando-Monge
Professor of Pathology and Associate Director of Research at New York University (NYU)
Dr. Andrew Tutt
Director of the Breast Cancer Now Toby Robins Research Centre at the Institute of Cancer Research, London. Professor of Oncology at King’s College London.
Dr. Josep Tabernero
Director of VHIO — Vall d’Hebron Institute of Oncology
Specialty: Molecular Oncology
Dr. Aleix Prat
Clínic Barcelona Comprehensive Cancer Center
Specialty: Breast Cancer and Precision Medicine
Dr. Andrés Cervantes
INCLIVA — Hospital Clínico de Valencia
Specialty: Digestive Oncology
Dr. Luís Paz-Ares
Hospital 12 de Octubre · Madrid
Specialty: Lung Cancer
Dr. Antoni Ribas
International Expert
Specialty: Oncological Immunotherapy